Singapore, March 18 -- India-based Cipla has announced an exclusive licensing agreement with Taiwan-based Formosa Pharmaceuticals for the commercialisation of clobetasol propionate ophthalmic suspension, 0.05% (APP13007).

Under this agreement, Cipla has exclusive rights to market the innovative treatment for post-operative inflammation and pain following ocular surgery across 11 countries such as India, South Africa, Nepal, Sri Lanka, Bangladesh, Malaysia, Myanmar, Kenya, Nigeria, Argentina, and Colombia.

APP13007 is a novel, patent protected and US FDA approved ophthalmic product. It offers a convenient twice-daily dosing regimen for 14 days without tapering, providing rapid and sustained relief from inflammation and pain. This new ste...